SlideShare una empresa de Scribd logo
1 de 73
Descargar para leer sin conexión
1
2
Arthur Dessi Roman MD MTM FPCP FPSMID
Internal Medicine – Infectious Diseases
Outline
• Basic Bacteriology
– Structure and Characteristics
– Bacterial Culture
• Host defenses
• Cases
– Gram positive Pathogens
– Gram negative Pathogens
– Bonus(es)
• Question and Answer Portion
• Sportswear Competition
3
Highschool recall: Eukaryotes
• Eukaryote - organism whose cells contain complex
structures enclosed within membranes
– the defining membrane-bound structure is the nucleus,
which contains the genetic material
– also contain other membrane-bound organelles:
mitochondria, chloroplasts and the Golgi apparatus
– e.g. animals, plants and fungi
Highschool recall: Prokaryotes
• Prokaryote - NO cell nucleus , or any other
membrane-bound organelles.
– DNA and other sites of metabolic activity: openly
accessible, free-floating
– asexual reproduction, usually by binary fission or budding
– Genetic exchange and recombination still occur, but this is
a form of horizontal gene transfer and is
NOT a replicative process, simply
involving the transference of DNA
between two cells, as in
bacterial conjugation.
4
Size comparison of cells
Bacterium
Bacterial cell structure
5
Prokaryotes Eukaryotes
Simple structure Membrane-bound structures
(nucleus, mitochondria)
Plasmids
Peptidoglycan that strengthens
bacterial cell wall
Bacterial morphology
6
Generalities
• Most cocci are gram positive
• Most bacilli are gram negative
Gram positive Bacilli/rods
• Bacillus sp.
– Normal flora of the skin
– B. anthracis, B. cereus
• Lactobacillus (shirota strain et al)
• Corynebacterium
• Clostridium sp.
• Listeria
• Erysipelothrix
7
Gram negative cocci
• N. meningitides, N. gonorrhea
• Acinetobacter spp.
• Coccobacilli:
– Pasteurella multocida
– Bordetella pertussis
– Legionella
Identify
8
Identify
Identify
9
Bacterial morphology
Gram staining
10
11
The Gram Stain
• Quick procedure that reveals bacterial cell
morphology (cocci vs. bacilli, G+ vs G-)
• Gram negative: red/pink
• Gram positive: violet/blue
• The color difference is based on the amount
of the peptidoglycan layer (G+=thick = more
dye uptake=blue/violet color)
• Results guide initial antibiotic therapy
The Prokaryotic genome has many
plasmids.
• encode genes that carry specialized functions
(eg. Resistance to bacteria)
• Also encode for genes that mediate their
transfer from one organism to another as well
as other genes associated with genetic
acquisition or rearrangement of DNA.
12
Rise of the superbugs
Resistance of bacteria to antibiotics after their liberal
use in hospitals may be assimilated by plasmids of
other non-resistant bacteria
Gram-positive vs Gram-negative cell wall
13
Gram-positive & Gram-negative cell wall
Gram + Gram -
Cell wall made of thick
peptidoglycan
Thin peptidoglycan
No outer membrane Outer membrane present
No endotoxin contains LPS/ Lipid A/ endotoxin
responsible for sepsis
More susceptible to penicillins
(lysozymes, detergents, etc.) due to
absence of outer layer
Outer membrane provides
barrier has porins for entry of
nutrients
NO periplasmic space Periplasmic space contains B-
lactamase/other enzymes that may
degrade antibiotics
Possess teichoic acids NO teichoic acids
14
Bacterial cell wall peptidoglycan
PBPs
• Penicillin-binding proteins (PBPs) catalyze the
synthesis of the PG in the cell wall
• B-lactam antibiotics work by inhibiting PBPs
• Some bacteria produce enzymes that alter the
PBPs or inactivate the B lactam ring 
resistance
15
Beta-Lactams
Sulbactam
• A beta-lactamase inhibitor
• Binds to B-lactamase irreversible B-lactamase
canNOT deactivate the beta-lactam ring
16
Beta-Lactams
Meropenem
17
(Livermore and Woodford, Trends in Microbiol, 2006)
The Gram Negative Cell Wall
Porin
channels
PBPs
Efflux system
B-lactamases
Mechanism of Resistance to β-lactams
CELL WALL
PENICILLIN BINDING
PROTEIN (cell wall
synthesis)
S. aureus
18
BETA-LACTAM ANTIBIOTIC
S. aureus
mecA gene
DNA
SCC
PBP2A
MRSA
19
Anaerobic vs. aerobic bacteria
• Aerobic: need oxygen to grow
• Anaerobic: fail to grow in the presence of oxygen
• Obligate anaerobes: grow only in aerobic environment
• Facultative anaerobes: can grow with or without oxygen
• Microaerophilic bacteria: grow best in an environment with
reduced oxygen
• Aerotolerant: can grow in the presence of air, but do NOT use
oxygen
Important Bacterial Pathogens
Bacteria
Gram positive* Gram negative* Atypical
Cocci Bacilli Cocci Bacilli
*can be aerobic/anaerobic
20
Spot Quiz
What are single-celled, prokaryotic
microorganisms that sometime produce disease
in humans and are usually susceptible to
antibiotics?
Answer: BACTERIA
21
What is the rigid structure outside the cell
membrane which protects and maintains the
shape of bacteria?
Answer: CELL WALL
What is the main component of bacterial cell
walls?
Answer: PEPTIDOGLYCAN
22
What are the proteins that facilitate formation
of peptidoglycans?
Answer: PENICILLIN-BINDING PROTEINS
(PBPs)
What is the procedure that can help visualize
bacteria under the microscope and differentiate
them into gram-positive and gram-negative
bacteria?
Answer: GRAM STAIN
23
Differentiate the call walls of gram-positive and
gram-negative cell walls.
Answer: Gram-negative cell walls have an outer
membrane made up of a thinner layer
of peptidoglycan and an outer
membrane, which is in turn made up
of lipopolysacharide or endotoxin.
What is the enzyme that can degrade beta
lactam antibiotics found in the periplasmic
space of gram-negative bacteria?
Answer: BETA LACTAMASE
24
The outer membrane of gram-negative bacteria
act as a barrier to some antibiotics, but
antibiotics and other nutrients can enter the
bacteria via “holes” called:
Answer: PORINS
Differentiate aerobes from anaerobes.
Answer: Aerobes are bacteria that need
oxygen to grow, while anaerobes
are bacteria that cannot grow in the
presence of oxygen.
25
Bacterial reproduction via binary fission
Bacterial culture
26
Bacterial Identification
• Subsequent bacterial identification is based
from initial Gram staining results from
bacteria from isolated colonies on agar plate
• Subsequent testing uses bacterial nutritional
requirement and metabolic capacities
• Most bacteria will grow in 24-48 hours except for
fastidious or anaerobes which may require more time.
• Culture/identification is performed so a physician can
come up with a diagnosis and prescribe the most
appropriate antibiotic.
27
Normal Flora
28
Bacterial growth curve
Pathogens
• Microorganisms causing disease
• Pathogenicity: ability to cause disease
(increased by the presence of bacterial
enzymes and bacterial toxins)
• Stages of infection: adherence, invasion,
multiplication, dissemination in the host
29
Host Defenses
Types of Infection
Acute: Chronic:
- develop rapidly - develop more slowly
- usually associated with fever - milder symptoms
- generally of short duration - longer-lasting
Acute infections may become chronic, chronic infections may
become acute.
Local: Systemic:
- Limited to one site - throughout the body
Local infections may occasionally cause systemic symptoms or
may serve as nucleus for spread of infection to other body
areas (e.g. dental infection).
30
Types of Infection
• Bacteremia: presence of bacteria in the blood.
• Septicemia: blood poisoning; systemic disease associated
with presence and persistence of pathogenic microorganisms
or their toxins in the blood.
Phases of Infection
1. Invasion: Bacteria gain entry into the host, or host tissues,
where it’s not part of normal flora.
2. Incubation: Period before any manifestation of illness. It
represents the time required for pathogens to multiply to a
critical population size. Patient can be infectious.
3. Prodrome: Period characterized by nonspecific symptoms
(e.g. headache, malaise).
4. Clinical illness: Period when specific symptoms (fever)
appear. Body damage may result due to toxin, death of host
cells, actions of host’s immune system.
5. Convalescence or Resolution: Period of recovery, even
without symptoms patient may still be infectious.
31
Symptoms of Infection
• Provide subjective information on patient’s condition.
• Inflammation: Process that occurs in tissues as a
reaction to injury. It involves vasodilation, increased
permeability of capillaries to fluid and large molecules,
and attraction and accumulation of WBCs and other
immune system components in injured area.
- Results in pain, swelling, heat and throbbing.
• Fever: Not true in all infections. Microbes produce
pyrogens (fever-causing substances) that cause release
of cytokines that cause the fever.
• Symptoms depend on organs or systems affected and
are helpful to MDs in diagnosing specific conditions.
Signs of Infection
• Provide objective measures of disease; vary depending on nature
and severity of condition.
• Fever: Both a sign and symptom.
• Increased number of neutrophils in blood.
• Increased in proportion of immature WBC (shift to the left).
• Neutropenia or granulocytopenia: abnormally, low neutrophils in
overwhelming, severe infections. (Normal value: 1,500-7,800 /mL).
The incidence of infection rises as neutrophil count declines.
• Anemia: reduction below normal in number of RBCs per mm3,
hemoglobin, or volume of packed RBC per 100 ml of blood.
• Increased ESR (erythrocyte sedimentation rate) which measures the
rate at which RBCs settle in uncoagulated blood – a non-specific
measure of inflammation or disease activity.
32
Signs of Infection
• Elevated blood levels of C-reactive protein.
• Increase in pulse rate, respiration rate, anxiety, confusion,
delirium, and other abnormalities in mental status.
• Hyperglycemia: elevated blood sugar levels, especially in
diabetics.
• Changes in kidney and liver function.
Non-specific host defenses
• Directed against any pathogen
• Mechanical
• Chemical
• Phagocytes and complement system
33
Non-specific immunity: cilia
Non-specific immunity: phagocytes
34
Specific immunity: antibodies
Specific immunity: T cells
35
Spot quiz(zes)
What do you call the microorganisms that
normally live in our bodies?
Answer: NORMAL FLORA
36
What do you call a microorganism that cause
disease?
Answer: PATHOGEN
What do you have when bacteria invade body
tissues, multiply in them, and cause damage to
the host’s cells?
Answer: INFECTION
37
What do you call the body’s response to
infection?
Answer: IMMUNITY
What is the importance of knowing the normal
flora in terms of dealing with infections?
Answer: It helps in determining
EMPIRIC THERAPY.
38
Antibiotic Classes
32
Case 1
• 35/male who was admitted for severe
abdominal pain and fever.
• Took paracetamol but did not improveER
• PE: febrile, direct and rebound tenderness
RLQ
39
32
Case 1
• A> Acute appendicitis  underwent OR
• He was discharged improved.
• On ff-up with the surgeon after 5 days,
STAPHYLOCOCCUS
40
Staphylococcus aureus
• frequently found in the human respiratory tract and on
the skin
• NOT always pathogenic
• Causes skin infections (e.g. boils), respiratory disease
(e.g. sinusitis), and food poisoning
• Producing potent toxins
• Common cause of device-related infections
• Carriage in healthy individuals (nostrils)
• The emergence of antibiotic-resistant forms of
pathogenic S. aureus (e.g. MRSA) is a worldwide
problem in clinical medicine.
Staphylococcus aureus
• Virulence factors
– Coagulase
– Staphylokinase
– Hyaluronidase
41
Coagulase and Staphylokinase
Staphylokinase
Staphylokinase
Clotting protein
36
Hyaluronidase (Spreading factor)
Hyaluronidase digests hyaluronic acid,
the “glue” that holds cells together
37
42
Clinical manifestation of S. aureus infection
38
40
43
Staphylococcus aureus
1. Local Stap. Infection – drainage
> antibiotics –semi synthetic PCN
Cloxacillin Erythromycin
Cehalosporin (1st gen.)
2. Systemic Infection: Parenteral
Vancomycin Oxacillin
Methiallin Cephalosporin
Question
What is the current MRSA rate in the Philippines
according to the ARSP 2014?
A. <5%
B. 35%
C. 60%
D. 90%
44
Question
What is the current MRSA rate in the Philippines
according to the ARSP 2014?
A. <5%
B. 35%
C. 60%
D. 90%
Percent resistance of S. aureus,
(n=3,529), ARSP, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM 2014 ANNUAL REPORT
FIGURE 32. Yearly penicillin, oxacillin and vancomycin resistance rates of S. aureus,
ARSP, 2005-2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT,
Research Institute for Tropical Medicine, Department of Health Philippines
45
Percent resistance of S. aureus,
(n=3,529), ARSP, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT,
Research Institute for Tropical Medicine, Department of Health Philippines
Percent resistance of S. aureus,
ARSP, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM 2014 ANNUAL REPORT
Antimicrobial Resistance
The 2014 resistance rate of S. aureus against the β-lactam oxacillin is at 60.3%
(n=3,323; 95% CI: 58.6-62). The 2014 rate of methicillin-resistant S. aureus (MRSA) rates
increased significantly from 53.2% in 2013 to the 60.3% in 2014 (p value 0.0001). Resistance
rates against the antibiotics tested against S. aureus for 2014 and the past decade are see n
FIGURES 40-43. The 2014 resistance rates to the rest of the antibiotics tested did not differ
significantly from the reports from 2013 except for the significant increase in co-trimoxazole
resistance from 14% in 2013 to 22% for 2014 (p value 0.0001). Although there were 17 isolates
reported as vancomycin resistant, none of these S. aureus isolates were sent for confirmatory
testing at the reference laboratory.
FIGURE 30. Percent resistance against penicillins, vancomycin, clindamycin and
erythromycin of S. aureus, ARSP, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT,
Research Institute for Tropical Medicine, Department of Health Philippines
• Overall cumulative MRSA rate for 2014 was at 60.3%
(from 53.2%, p=0.0001)
• 85% were isolated from specimens taken from patients in
the OPD, emergency room and admission within their 1st
2 hospital days
• 60% MRSA rate from all blood isolates (n=570)
46
Enterococci
• Gram-positive cocci in chain
44
Enterococci
• Gram-positive cocci in chain
• Commensals of the GI tract of humans & animals
• Diseases :
• Consist of 16 species :- E. faecalis, E. faecium
- Urinary tract infection (UTI)
- Bacteremia, endocarditis
44
47
Vancomycin-Resistant
Enterococci (VRE)
46
• An emerging pathogen but none yet in PH
• Acquired via plasmids
• Cephalosporin use is a risk factor
• Can be carried by healthy people
32
Case 2
• 65/male DM, HPN admitted for sudden left
sided weaknessER
• PE: no motor movement left UE and LE,
shallow right NSLF, slurred speech
48
32
Case 2
• Treated as stroke and underwent rehab after 5
days doing well
• On Day 6 cough and difficulty of breathing,
high fever, auscultation revealed rales on right
lung field
• Eventually intubated due to respiratory
distress
Case 2
• Started empirically on PipTazo
• ETA GS revealed many PMNs and many Gram
_____________.
49
Pseudomonas aeruginosa
•Aerobic gram-negative bacilli, non-
spore forming
•Produces cyanin pigment
•Produces grape-like odor
•Inhabitant of the GI tract
•Saprophytic (natural habitat: soil
and water)
•An opportunistic pathogen
Pseudomonas aeruginosa
•
50
• MOST important hospital-acquired pathogen
• Other pseudomonads: Burkholderia mallei,
Burkholderia cepacia
•High tendency to develop antibiotic resistance
Pseudomonas aeruginosa
21
Resistance Pattern of P. aeruginosa, ARSP 2011
51
23
• Causes nosocomial infections- extensive burns, trauma
to the skin or conjunctiva, urinary tract manipulations
• cystic fibrosis.
• Ear infections – swimmer’s ear
• Bacteremia in debilitated patients, accounts for 10% of
all Gram(-) associated with a 50% mortality rate
Pseudomonas aeruginosa
21
52
Treatment
• Aminoglycosides
• Third and fourth generation cephalosporins
(ceftazidime, cefepime)
• Carbapenems (imipenem, meropenem)
• Pip-tazo
• Colistin
Pseudomonas aeruginosa
Clinical manifestation of P. aeruginosa
infections
53
32
Case 3
• 15/male with cerebral palsy recurrently
admitted for pneumonia
• He already has a tracheostomy tube in place
• Developed progressive cough and respiratory
distressER
32
Case 3
• PE: drowsy, highly febrile, rales all over R>L
• Hooked to MV and started on Pip-Tazo
54
Case 3
• After 3 days of antibiotics, he was still febrile
• Developed hypotension and further
respiratory distress
Case 4
• EC = few PMN=moderate
• Gram negative diplococci-few
• Gram negative coccobacilli-many
55
Acinetobacter
• Aerobic gram-negative coccobacilli,
non-spore forming
• > 25 species
• A common cause of ventilator-
associated pneumonia (VAP)
• Opportunistic pathogen
28
• Local isolates are very highly
resistant to antibiotics
A. baumannii
Clinical manifestation of A. baumannii
infection1.Hospital-acquired pneumonia
especially VAP
2.Community-acquired pneumonia
:The source of infection may be throat
carriage, which occurs in 10% of
community residents with excessive
alcohol consumption
3.Bloodstream infection & endocarditis
4.Skin/soft tissue infection
5.UTI
6.Meningitis
29
56
A. baumannii
Persistence in the hospital
environment : 3 days to 5 months
1. Resistance to major antimicrobial
drugs
2. Resistance to desiccation
3. Resistance to disinfectant
Three factors contributing to the
persistence
31
A. baumannii
31
57
A. baumannii
Treatment:
• Meropenem
• Colistin
• Tigecycline
• Ampicillin-Sulbactam
31
Acinetobacter
• Aerobic gram-negative coccobacilli,
non-spore forming
• > 25 species
• A common cause of ventilator-
associated pneumonia (VAP)
• Opportunistic pathogen
28
• Local isolates are very highly
resistant to antibiotics
58
A. baumannii
Clinical manifestation of A. baumannii
infection1.Hospital-acquired pneumonia
especially VAP
2.Community-acquired pneumonia
:The source of infection may be throat
carriage, which occurs in 10% of
community residents with excessive
alcohol consumption
3.Bloodstream infection & endocarditis
4.Skin/soft tissue infection
5.UTI
6.Meningitis
29
A. baumannii
Persistence in the hospital
environment : 3 days to 5 months
1. Resistance to major antimicrobial
drugs
2. Resistance to desiccation
3. Resistance to disinfectant
Three factors contributing to the
persistence
31
59
A. baumannii
31
A. baumannii
Treatment:
• Meropenem
• Colistin
• Tigecycline
• Ampicillin-Sulbactam
31
60
Enterobactereaceae
• Gram-negative, nonspore-forming rods
• Facultative anaerobic
• Grow in simple media (MacConkey agar)
• Ferment glucose (LF)
• Motile with peritrichous flagella except Shigella
• Some possess capsule
Impt. Human pathogens
• Escherichia - E. coli
• Enterobacter (E. aerogenes, E. cloacae)
• Citrobacter - C. freundii
• Serratia - S. marcescens
• Hafnia - H. alvei
• Klebsiella
61
*Proteus Group
– P. mirabilis
– P. vulgaris
– Morganella – M. morganii
– Providencia – P. rettgeri
*Edwardsiella – E. hoshinae
Escherichia coli
• Escherichia coli and certain related bacteria (e.g.,
Klebsiella, Enterobacter, Citrobacter) form the
group known as the coliforms
• presence in drinking water is considered evidence
of fecal contamination
• used as an index of fecal pollution.
62
Epidemiology
• Fecal-oral transmission transmission among infants in
hospital nurseries.
• Food-borne transmission of E. coli 0157:H7 -
contaminated meat, from cattle; this serotype behaves as
a zoonotic agent.
• UTI –perineum; In women, UTI is associated with sexual
activity, hence the term "honeymoon cystitis".
Diseases associated with
Escherichia coli:
• Diarrhea
• Meningitis – impt. cause of neonatal
meningitis in the neonates
• Sepsis
• Urinary Tract Infection -most
common cause
63
Gram’s Stain and Culture
Klebsiellae
• Encapsulated
• The species of Klebsiella include
- Klebsiella pneumoniae- most infections
-Klebsiella oxytoca
-Klebsiella ozaenae
-Klebsiella rhinoscleromatis
64
• Mucoid colony
• มีแคปซูลหนา
Klebsiella
18
Diseases:
• Community acquired and nosocomial
pneumonia w/ underlying medical problems
such as alcoholism, COPD or diabetes mellitus
• Lung abscess may also develop.
• Urinary tract infection
• Wound infection
• Epidemic diarrhea - newborns
• Septicemia
65
• Hypermotile
• Swarming
growth
Proteus vulgaris
66
Enterobacteriaceae: Treatment
• Empiric therapy with aminoglycoside and
third cephalosporin
Case 4
• 35/female who just delivered a baby boy via
NSD 1 week ago rushed back to the ER for
severe hypogastric pain
• PE: highly febrile, direct tenderness at the
hypogastric area, purulent vaginal discharge
• Diagnosis?
• Started on meropenem and clindamycin
(MRSA)
67
Case 4
• She underwent EL on Day 3
• Doing well
• Day 10 of meropenem and clinda, developed
high fever
• No cough. No dysuria but she was having LBM
5-7x/day
• Diagnosis?
Clostridium Difficile
• Gm (+) bacillus, obligate anaerobe
• Spore forming contact precautions
• Causes pseudomembranous colitis and
antibiotic-associated diarrhea
68
Laboratory Diagnosis
• Culture of stool specimens
• Cytotoxin Assay
– Tissue culture assay
– immunoassays
• Colonoscopy or Signoidoscopy with Biopsy
Endoscopic findings – pseudomembranes and
hyperemic rectal mucosa
Treatment
• Antimicrobial therapy should be
discontinued
• Maintenance of fluid & electrolyte balance
• Avoid drugs which intestinal motility
69
• Drug of choice
– Metronidazole (30 mg/day in 4 divided
doses) – drug of choice in the initial
treatment of most patients with colitis
– Oral Vancomycin (40 mg/kg/day in 4 divided
doses) – indicated only for seriously ill
patients or those who do not respond to
vancomycin
– Bacitracin – ssecond alternative therapeutic
choice
Case 5
• 70/female post stroke and chronically bed
ridden was admitted for decreased sensorium
• Because of urinary incontinence, has been on
foley catheter and PEG for episodes of
aspiration
• PE: drowsy, T 37 C BP 70/50 HR 100
• Clear breath sounds, no nuchal rigidity
70
Case 5
• Labs done: WBC 20 Neut 90%
• Chest xray: normal
• Urinalysis: WBC 50 RBC 0-3 EC few yeast cells
few
• Started on Ceftriaxone 1g IV q24h
• FC was changed
• Urine GS CS requested
Case 5
• Urine GS: PMN many yeast cells few G+cocci
in clusters many
71
Candida spp.
• normal flora of the skin, mucous membranes, and
gastrointestinal tract
• colonize the mucosal surfaces of all humans during or soon
after birth
• Candida albicans – the most common pathogen
• Others: C albicans, C tropicalis, C parapsilosis, C glabrata, C
guilliermondii, and C dubliniensis)
• The widespread use of fluconazole has precipitated the
emergence of more azole-resistant species, such as C krusei
and C lusitaniae.
Cutaneous & Mucosal Candidiasis
• The risk factors: AIDS, pregnancy, diabetes, young or old age,
birth control pills, and trauma (burns, maceration of the skin),
corticosteroids or antibiotics, hyerglycemia, and cellular
immunodeficiency
• Cutaneous candidiasis- when the skin is weakened by trauma,
burns, or maceration.
Vulvovaginitis - irritation, pruritus, and vaginal discharge;
often preceded by factors such as diabetes, pregnancy, or
antibacterial drugs that alter the microbial flora, local acidity,
or secretions.
72
Systemic Candidiasis (Candidemia)
• Causes:
– indwelling catheters, surgery, intravenous drug abuse,
aspiration, or damage to the skin or gastrointestinal tract
• most often associated with:
– chronic administration of corticosteroids or other
immunosuppressive agents; with hematologic diseases
such as leukemia, lymphoma, and aplastic anemia; or with
chronic granulomatous disease
Candidiasis: Treatment
• Systemic candidiasis: amphotericin B with/without oral
flucytosine, fluconazole, or caspofungin
73
Outline
• Basic Bacteriology
– Structure and Characteristics
– Bacterial Culture
• Host defenses
• Gram positive Pathogens
• Gram negative Pathogens
• Bonus(es)
감사합니다!!!! ㅋㅋㅋ

Más contenido relacionado

La actualidad más candente

Asp antimicrobial stewardship
Asp antimicrobial stewardshipAsp antimicrobial stewardship
Asp antimicrobial stewardshipMEEQAT HOSPITAL
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Tahseen Siddiqui
 
Antimicrobial Stewardship
Antimicrobial StewardshipAntimicrobial Stewardship
Antimicrobial StewardshipFatmaAtef10
 
Antimicrobial Stewardship ,Heba Abdallatif,BCPS
Antimicrobial Stewardship  ,Heba Abdallatif,BCPSAntimicrobial Stewardship  ,Heba Abdallatif,BCPS
Antimicrobial Stewardship ,Heba Abdallatif,BCPSHeba Abd Allatif
 
Antibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativeAntibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativePYA, P.C.
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)BBrauer25
 
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesDr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesJohn Blue
 
Advisor Live: Antimicrobial Stewardship - Why Now and How?
Advisor Live: Antimicrobial Stewardship - Why Now and How?Advisor Live: Antimicrobial Stewardship - Why Now and How?
Advisor Live: Antimicrobial Stewardship - Why Now and How?Premier Inc.
 
Role of the Laboratory in Antimicrobial Resistance Data
Role of the Laboratory in Antimicrobial Resistance DataRole of the Laboratory in Antimicrobial Resistance Data
Role of the Laboratory in Antimicrobial Resistance DataAnuj Sharma
 
Antibiotic Resistance
Antibiotic ResistanceAntibiotic Resistance
Antibiotic ResistanceSayantanDas85
 
29 nov pct guided antibiotic use
29 nov pct guided antibiotic use29 nov pct guided antibiotic use
29 nov pct guided antibiotic usePathKind Labs
 
Patient safety goal 4 : Tackling Antimicrobial Resistance
Patient safety goal 4  : Tackling Antimicrobial ResistancePatient safety goal 4  : Tackling Antimicrobial Resistance
Patient safety goal 4 : Tackling Antimicrobial ResistanceHCY 7102
 
Antibiotic stewardship program pk pd approach
Antibiotic stewardship program pk pd approach  Antibiotic stewardship program pk pd approach
Antibiotic stewardship program pk pd approach Dr Asish Kumar Saha
 
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...John Blue
 
Who antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurWho antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurAshish Gupta
 

La actualidad más candente (20)

DOH Antimicrobial Stewardship Program in Hospitals Manual of Procedures (MOP)...
DOH Antimicrobial Stewardship Program in Hospitals Manual of Procedures (MOP)...DOH Antimicrobial Stewardship Program in Hospitals Manual of Procedures (MOP)...
DOH Antimicrobial Stewardship Program in Hospitals Manual of Procedures (MOP)...
 
Asp antimicrobial stewardship
Asp antimicrobial stewardshipAsp antimicrobial stewardship
Asp antimicrobial stewardship
 
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
 
Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19Antimicrobial stewardship CME 04-03-19
Antimicrobial stewardship CME 04-03-19
 
Antimicrobial Stewardship
Antimicrobial StewardshipAntimicrobial Stewardship
Antimicrobial Stewardship
 
Antimicrobial Stewardship ,Heba Abdallatif,BCPS
Antimicrobial Stewardship  ,Heba Abdallatif,BCPSAntimicrobial Stewardship  ,Heba Abdallatif,BCPS
Antimicrobial Stewardship ,Heba Abdallatif,BCPS
 
Antibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativeAntibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International Imperative
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)
 
Who antibiotic policy
Who antibiotic policyWho antibiotic policy
Who antibiotic policy
 
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesDr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health Examples
 
Advisor Live: Antimicrobial Stewardship - Why Now and How?
Advisor Live: Antimicrobial Stewardship - Why Now and How?Advisor Live: Antimicrobial Stewardship - Why Now and How?
Advisor Live: Antimicrobial Stewardship - Why Now and How?
 
Role of the Laboratory in Antimicrobial Resistance Data
Role of the Laboratory in Antimicrobial Resistance DataRole of the Laboratory in Antimicrobial Resistance Data
Role of the Laboratory in Antimicrobial Resistance Data
 
Antibiotic Resistance
Antibiotic ResistanceAntibiotic Resistance
Antibiotic Resistance
 
29 nov pct guided antibiotic use
29 nov pct guided antibiotic use29 nov pct guided antibiotic use
29 nov pct guided antibiotic use
 
Patient safety goal 4 : Tackling Antimicrobial Resistance
Patient safety goal 4  : Tackling Antimicrobial ResistancePatient safety goal 4  : Tackling Antimicrobial Resistance
Patient safety goal 4 : Tackling Antimicrobial Resistance
 
Antibiotic stewardship program pk pd approach
Antibiotic stewardship program pk pd approach  Antibiotic stewardship program pk pd approach
Antibiotic stewardship program pk pd approach
 
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...
Dr. Theoklis Zaoutis - Antimicrobial Use and Stewardship in the Pediatric Out...
 
Antimicrobial Stewardship
Antimicrobial StewardshipAntimicrobial Stewardship
Antimicrobial Stewardship
 
Who antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurWho antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipur
 
ANTIBIOTIC STEWARDSHIP CURRENT UPDATES
ANTIBIOTIC STEWARDSHIP  CURRENT UPDATES ANTIBIOTIC STEWARDSHIP  CURRENT UPDATES
ANTIBIOTIC STEWARDSHIP CURRENT UPDATES
 

Similar a World of Microbes

Multi drug resistance molecular pathogenesis
Multi drug resistance   molecular pathogenesisMulti drug resistance   molecular pathogenesis
Multi drug resistance molecular pathogenesisAlagar Suresh
 
1+2 bacteria 1.pdf
1+2 bacteria 1.pdf1+2 bacteria 1.pdf
1+2 bacteria 1.pdfIftikhar70
 
Basic immunology dr rk ent
Basic immunology dr rk entBasic immunology dr rk ent
Basic immunology dr rk entraju kafle
 
9- Introduction to Virology and Prions.pptx
9- Introduction to Virology and Prions.pptx9- Introduction to Virology and Prions.pptx
9- Introduction to Virology and Prions.pptxAbdallahAlasal1
 
Microbes, Man and Environment (Microbial pathogenicity) .pptx
Microbes, Man and Environment (Microbial pathogenicity) .pptxMicrobes, Man and Environment (Microbial pathogenicity) .pptx
Microbes, Man and Environment (Microbial pathogenicity) .pptxMidhatSarfraz
 
Pharmacokinetics and pharmacodynamics of biotechnology drugs
Pharmacokinetics and pharmacodynamics of biotechnology drugsPharmacokinetics and pharmacodynamics of biotechnology drugs
Pharmacokinetics and pharmacodynamics of biotechnology drugsRaviK172
 
The immune system
The immune systemThe immune system
The immune systemChy Yong
 
Antibiotics handbook by Dr Aneek Gupta
Antibiotics handbook by Dr Aneek GuptaAntibiotics handbook by Dr Aneek Gupta
Antibiotics handbook by Dr Aneek GuptaDr Aneek Gupta
 
Immunity against microbial infections dr.ihsan alsaimary
Immunity against microbial infections dr.ihsan alsaimaryImmunity against microbial infections dr.ihsan alsaimary
Immunity against microbial infections dr.ihsan alsaimarydr.Ihsan alsaimary
 
Immunodeficieny states lecture notes
Immunodeficieny states lecture notesImmunodeficieny states lecture notes
Immunodeficieny states lecture notesBruno Mmassy
 
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptx
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptxBACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptx
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptxanshulsharma905846
 
Bacterial structure.pptx
Bacterial structure.pptxBacterial structure.pptx
Bacterial structure.pptxShahriarHabib4
 
principles of antimicrobial.pptx
principles of antimicrobial.pptxprinciples of antimicrobial.pptx
principles of antimicrobial.pptxrupeshdalavi
 
principles of antimicrobial therapy (1).pptx
principles of antimicrobial therapy (1).pptxprinciples of antimicrobial therapy (1).pptx
principles of antimicrobial therapy (1).pptxogadatv
 
molecular mechanism of pathogenesis
 molecular mechanism of pathogenesis molecular mechanism of pathogenesis
molecular mechanism of pathogenesisBilal Nasir
 
Topic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionTopic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionjayarajgr
 
Topic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionTopic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionjayarajgr
 
3. inflammation best.ppt
3. inflammation best.ppt3. inflammation best.ppt
3. inflammation best.pptMesfinShifara
 
MICRO FOR nurses introduction to microbiology
MICRO FOR nurses introduction to microbiologyMICRO FOR nurses introduction to microbiology
MICRO FOR nurses introduction to microbiologyajadoon84
 
Mechanism of pathogenicity-Exotoxin and endotoxin
Mechanism of pathogenicity-Exotoxin and endotoxinMechanism of pathogenicity-Exotoxin and endotoxin
Mechanism of pathogenicity-Exotoxin and endotoxinaiswarya thomas
 

Similar a World of Microbes (20)

Multi drug resistance molecular pathogenesis
Multi drug resistance   molecular pathogenesisMulti drug resistance   molecular pathogenesis
Multi drug resistance molecular pathogenesis
 
1+2 bacteria 1.pdf
1+2 bacteria 1.pdf1+2 bacteria 1.pdf
1+2 bacteria 1.pdf
 
Basic immunology dr rk ent
Basic immunology dr rk entBasic immunology dr rk ent
Basic immunology dr rk ent
 
9- Introduction to Virology and Prions.pptx
9- Introduction to Virology and Prions.pptx9- Introduction to Virology and Prions.pptx
9- Introduction to Virology and Prions.pptx
 
Microbes, Man and Environment (Microbial pathogenicity) .pptx
Microbes, Man and Environment (Microbial pathogenicity) .pptxMicrobes, Man and Environment (Microbial pathogenicity) .pptx
Microbes, Man and Environment (Microbial pathogenicity) .pptx
 
Pharmacokinetics and pharmacodynamics of biotechnology drugs
Pharmacokinetics and pharmacodynamics of biotechnology drugsPharmacokinetics and pharmacodynamics of biotechnology drugs
Pharmacokinetics and pharmacodynamics of biotechnology drugs
 
The immune system
The immune systemThe immune system
The immune system
 
Antibiotics handbook by Dr Aneek Gupta
Antibiotics handbook by Dr Aneek GuptaAntibiotics handbook by Dr Aneek Gupta
Antibiotics handbook by Dr Aneek Gupta
 
Immunity against microbial infections dr.ihsan alsaimary
Immunity against microbial infections dr.ihsan alsaimaryImmunity against microbial infections dr.ihsan alsaimary
Immunity against microbial infections dr.ihsan alsaimary
 
Immunodeficieny states lecture notes
Immunodeficieny states lecture notesImmunodeficieny states lecture notes
Immunodeficieny states lecture notes
 
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptx
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptxBACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptx
BACTERIAL PATHOGENICITY AND VIRULENCE FACTORS.pptx
 
Bacterial structure.pptx
Bacterial structure.pptxBacterial structure.pptx
Bacterial structure.pptx
 
principles of antimicrobial.pptx
principles of antimicrobial.pptxprinciples of antimicrobial.pptx
principles of antimicrobial.pptx
 
principles of antimicrobial therapy (1).pptx
principles of antimicrobial therapy (1).pptxprinciples of antimicrobial therapy (1).pptx
principles of antimicrobial therapy (1).pptx
 
molecular mechanism of pathogenesis
 molecular mechanism of pathogenesis molecular mechanism of pathogenesis
molecular mechanism of pathogenesis
 
Topic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionTopic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revision
 
Topic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revisionTopic 6 infection, immunity and forensics revision
Topic 6 infection, immunity and forensics revision
 
3. inflammation best.ppt
3. inflammation best.ppt3. inflammation best.ppt
3. inflammation best.ppt
 
MICRO FOR nurses introduction to microbiology
MICRO FOR nurses introduction to microbiologyMICRO FOR nurses introduction to microbiology
MICRO FOR nurses introduction to microbiology
 
Mechanism of pathogenicity-Exotoxin and endotoxin
Mechanism of pathogenicity-Exotoxin and endotoxinMechanism of pathogenicity-Exotoxin and endotoxin
Mechanism of pathogenicity-Exotoxin and endotoxin
 

Más de Philippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.

Más de Philippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc. (20)

Outbreak Investigation of Healthcare Associated Infections
Outbreak Investigation of Healthcare Associated InfectionsOutbreak Investigation of Healthcare Associated Infections
Outbreak Investigation of Healthcare Associated Infections
 
Epidemiology and Hand Hygiene
Epidemiology and Hand HygieneEpidemiology and Hand Hygiene
Epidemiology and Hand Hygiene
 
Epidemics and Epidemic Investigation
Epidemics and Epidemic InvestigationEpidemics and Epidemic Investigation
Epidemics and Epidemic Investigation
 
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
 
2016 WHO Guidelines on the Prevention of Surgical Site Infection (SSI)
2016 WHO Guidelines on the Prevention of Surgical Site Infection (SSI)2016 WHO Guidelines on the Prevention of Surgical Site Infection (SSI)
2016 WHO Guidelines on the Prevention of Surgical Site Infection (SSI)
 
PIDSR
PIDSRPIDSR
PIDSR
 
Local Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and ControlLocal Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and Control
 
Nurses No Harm
Nurses No HarmNurses No Harm
Nurses No Harm
 
DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)
 
DOH National Antibiotic Guidelines 2016 (Surgical Prophylaxis)
DOH National Antibiotic Guidelines 2016 (Surgical Prophylaxis)DOH National Antibiotic Guidelines 2016 (Surgical Prophylaxis)
DOH National Antibiotic Guidelines 2016 (Surgical Prophylaxis)
 
Surgical Site Infection (SSI)
Surgical Site Infection (SSI)Surgical Site Infection (SSI)
Surgical Site Infection (SSI)
 
Orientation to Surveillance
Orientation to SurveillanceOrientation to Surveillance
Orientation to Surveillance
 
HAI Surveillance Definitions and Standardizations
HAI Surveillance Definitions and StandardizationsHAI Surveillance Definitions and Standardizations
HAI Surveillance Definitions and Standardizations
 
Basic HAI Surveillance
Basic HAI SurveillanceBasic HAI Surveillance
Basic HAI Surveillance
 
Outbreak Investigation
Outbreak InvestigationOutbreak Investigation
Outbreak Investigation
 
Healthcare Workers’ Risks and Handling Exposures
Healthcare Workers’ Risks and Handling ExposuresHealthcare Workers’ Risks and Handling Exposures
Healthcare Workers’ Risks and Handling Exposures
 
Emerging and Re-emerging Infectious Diseases
Emerging and Re-emerging Infectious DiseasesEmerging and Re-emerging Infectious Diseases
Emerging and Re-emerging Infectious Diseases
 
Proper Donning and Doffing of PPE
Proper Donning and Doffing of PPEProper Donning and Doffing of PPE
Proper Donning and Doffing of PPE
 
Pharmacy
PharmacyPharmacy
Pharmacy
 
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
Ventilator Associated Pneumonia (VAP) or Hospital Acquired Pneumonia (HAP)
 

Último

NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxHanineHassan2
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYRMC
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learningNehaKewat
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychologyshantisphysio
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11crzljavier
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLyons Health
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementIris Thiele Isip-Tan
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)bishwabandhuniraula
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxPamela McKinney
 

Último (20)

NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learning
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychology
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
Annual Training
Annual TrainingAnnual Training
Annual Training
 
SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptx
 

World of Microbes

  • 1. 1
  • 2. 2 Arthur Dessi Roman MD MTM FPCP FPSMID Internal Medicine – Infectious Diseases Outline • Basic Bacteriology – Structure and Characteristics – Bacterial Culture • Host defenses • Cases – Gram positive Pathogens – Gram negative Pathogens – Bonus(es) • Question and Answer Portion • Sportswear Competition
  • 3. 3 Highschool recall: Eukaryotes • Eukaryote - organism whose cells contain complex structures enclosed within membranes – the defining membrane-bound structure is the nucleus, which contains the genetic material – also contain other membrane-bound organelles: mitochondria, chloroplasts and the Golgi apparatus – e.g. animals, plants and fungi Highschool recall: Prokaryotes • Prokaryote - NO cell nucleus , or any other membrane-bound organelles. – DNA and other sites of metabolic activity: openly accessible, free-floating – asexual reproduction, usually by binary fission or budding – Genetic exchange and recombination still occur, but this is a form of horizontal gene transfer and is NOT a replicative process, simply involving the transference of DNA between two cells, as in bacterial conjugation.
  • 4. 4 Size comparison of cells Bacterium Bacterial cell structure
  • 5. 5 Prokaryotes Eukaryotes Simple structure Membrane-bound structures (nucleus, mitochondria) Plasmids Peptidoglycan that strengthens bacterial cell wall Bacterial morphology
  • 6. 6 Generalities • Most cocci are gram positive • Most bacilli are gram negative Gram positive Bacilli/rods • Bacillus sp. – Normal flora of the skin – B. anthracis, B. cereus • Lactobacillus (shirota strain et al) • Corynebacterium • Clostridium sp. • Listeria • Erysipelothrix
  • 7. 7 Gram negative cocci • N. meningitides, N. gonorrhea • Acinetobacter spp. • Coccobacilli: – Pasteurella multocida – Bordetella pertussis – Legionella Identify
  • 10. 10
  • 11. 11 The Gram Stain • Quick procedure that reveals bacterial cell morphology (cocci vs. bacilli, G+ vs G-) • Gram negative: red/pink • Gram positive: violet/blue • The color difference is based on the amount of the peptidoglycan layer (G+=thick = more dye uptake=blue/violet color) • Results guide initial antibiotic therapy The Prokaryotic genome has many plasmids. • encode genes that carry specialized functions (eg. Resistance to bacteria) • Also encode for genes that mediate their transfer from one organism to another as well as other genes associated with genetic acquisition or rearrangement of DNA.
  • 12. 12 Rise of the superbugs Resistance of bacteria to antibiotics after their liberal use in hospitals may be assimilated by plasmids of other non-resistant bacteria Gram-positive vs Gram-negative cell wall
  • 13. 13 Gram-positive & Gram-negative cell wall Gram + Gram - Cell wall made of thick peptidoglycan Thin peptidoglycan No outer membrane Outer membrane present No endotoxin contains LPS/ Lipid A/ endotoxin responsible for sepsis More susceptible to penicillins (lysozymes, detergents, etc.) due to absence of outer layer Outer membrane provides barrier has porins for entry of nutrients NO periplasmic space Periplasmic space contains B- lactamase/other enzymes that may degrade antibiotics Possess teichoic acids NO teichoic acids
  • 14. 14 Bacterial cell wall peptidoglycan PBPs • Penicillin-binding proteins (PBPs) catalyze the synthesis of the PG in the cell wall • B-lactam antibiotics work by inhibiting PBPs • Some bacteria produce enzymes that alter the PBPs or inactivate the B lactam ring  resistance
  • 15. 15 Beta-Lactams Sulbactam • A beta-lactamase inhibitor • Binds to B-lactamase irreversible B-lactamase canNOT deactivate the beta-lactam ring
  • 17. 17 (Livermore and Woodford, Trends in Microbiol, 2006) The Gram Negative Cell Wall Porin channels PBPs Efflux system B-lactamases Mechanism of Resistance to β-lactams CELL WALL PENICILLIN BINDING PROTEIN (cell wall synthesis) S. aureus
  • 18. 18 BETA-LACTAM ANTIBIOTIC S. aureus mecA gene DNA SCC PBP2A MRSA
  • 19. 19 Anaerobic vs. aerobic bacteria • Aerobic: need oxygen to grow • Anaerobic: fail to grow in the presence of oxygen • Obligate anaerobes: grow only in aerobic environment • Facultative anaerobes: can grow with or without oxygen • Microaerophilic bacteria: grow best in an environment with reduced oxygen • Aerotolerant: can grow in the presence of air, but do NOT use oxygen Important Bacterial Pathogens Bacteria Gram positive* Gram negative* Atypical Cocci Bacilli Cocci Bacilli *can be aerobic/anaerobic
  • 20. 20 Spot Quiz What are single-celled, prokaryotic microorganisms that sometime produce disease in humans and are usually susceptible to antibiotics? Answer: BACTERIA
  • 21. 21 What is the rigid structure outside the cell membrane which protects and maintains the shape of bacteria? Answer: CELL WALL What is the main component of bacterial cell walls? Answer: PEPTIDOGLYCAN
  • 22. 22 What are the proteins that facilitate formation of peptidoglycans? Answer: PENICILLIN-BINDING PROTEINS (PBPs) What is the procedure that can help visualize bacteria under the microscope and differentiate them into gram-positive and gram-negative bacteria? Answer: GRAM STAIN
  • 23. 23 Differentiate the call walls of gram-positive and gram-negative cell walls. Answer: Gram-negative cell walls have an outer membrane made up of a thinner layer of peptidoglycan and an outer membrane, which is in turn made up of lipopolysacharide or endotoxin. What is the enzyme that can degrade beta lactam antibiotics found in the periplasmic space of gram-negative bacteria? Answer: BETA LACTAMASE
  • 24. 24 The outer membrane of gram-negative bacteria act as a barrier to some antibiotics, but antibiotics and other nutrients can enter the bacteria via “holes” called: Answer: PORINS Differentiate aerobes from anaerobes. Answer: Aerobes are bacteria that need oxygen to grow, while anaerobes are bacteria that cannot grow in the presence of oxygen.
  • 25. 25 Bacterial reproduction via binary fission Bacterial culture
  • 26. 26 Bacterial Identification • Subsequent bacterial identification is based from initial Gram staining results from bacteria from isolated colonies on agar plate • Subsequent testing uses bacterial nutritional requirement and metabolic capacities • Most bacteria will grow in 24-48 hours except for fastidious or anaerobes which may require more time. • Culture/identification is performed so a physician can come up with a diagnosis and prescribe the most appropriate antibiotic.
  • 28. 28 Bacterial growth curve Pathogens • Microorganisms causing disease • Pathogenicity: ability to cause disease (increased by the presence of bacterial enzymes and bacterial toxins) • Stages of infection: adherence, invasion, multiplication, dissemination in the host
  • 29. 29 Host Defenses Types of Infection Acute: Chronic: - develop rapidly - develop more slowly - usually associated with fever - milder symptoms - generally of short duration - longer-lasting Acute infections may become chronic, chronic infections may become acute. Local: Systemic: - Limited to one site - throughout the body Local infections may occasionally cause systemic symptoms or may serve as nucleus for spread of infection to other body areas (e.g. dental infection).
  • 30. 30 Types of Infection • Bacteremia: presence of bacteria in the blood. • Septicemia: blood poisoning; systemic disease associated with presence and persistence of pathogenic microorganisms or their toxins in the blood. Phases of Infection 1. Invasion: Bacteria gain entry into the host, or host tissues, where it’s not part of normal flora. 2. Incubation: Period before any manifestation of illness. It represents the time required for pathogens to multiply to a critical population size. Patient can be infectious. 3. Prodrome: Period characterized by nonspecific symptoms (e.g. headache, malaise). 4. Clinical illness: Period when specific symptoms (fever) appear. Body damage may result due to toxin, death of host cells, actions of host’s immune system. 5. Convalescence or Resolution: Period of recovery, even without symptoms patient may still be infectious.
  • 31. 31 Symptoms of Infection • Provide subjective information on patient’s condition. • Inflammation: Process that occurs in tissues as a reaction to injury. It involves vasodilation, increased permeability of capillaries to fluid and large molecules, and attraction and accumulation of WBCs and other immune system components in injured area. - Results in pain, swelling, heat and throbbing. • Fever: Not true in all infections. Microbes produce pyrogens (fever-causing substances) that cause release of cytokines that cause the fever. • Symptoms depend on organs or systems affected and are helpful to MDs in diagnosing specific conditions. Signs of Infection • Provide objective measures of disease; vary depending on nature and severity of condition. • Fever: Both a sign and symptom. • Increased number of neutrophils in blood. • Increased in proportion of immature WBC (shift to the left). • Neutropenia or granulocytopenia: abnormally, low neutrophils in overwhelming, severe infections. (Normal value: 1,500-7,800 /mL). The incidence of infection rises as neutrophil count declines. • Anemia: reduction below normal in number of RBCs per mm3, hemoglobin, or volume of packed RBC per 100 ml of blood. • Increased ESR (erythrocyte sedimentation rate) which measures the rate at which RBCs settle in uncoagulated blood – a non-specific measure of inflammation or disease activity.
  • 32. 32 Signs of Infection • Elevated blood levels of C-reactive protein. • Increase in pulse rate, respiration rate, anxiety, confusion, delirium, and other abnormalities in mental status. • Hyperglycemia: elevated blood sugar levels, especially in diabetics. • Changes in kidney and liver function. Non-specific host defenses • Directed against any pathogen • Mechanical • Chemical • Phagocytes and complement system
  • 35. 35 Spot quiz(zes) What do you call the microorganisms that normally live in our bodies? Answer: NORMAL FLORA
  • 36. 36 What do you call a microorganism that cause disease? Answer: PATHOGEN What do you have when bacteria invade body tissues, multiply in them, and cause damage to the host’s cells? Answer: INFECTION
  • 37. 37 What do you call the body’s response to infection? Answer: IMMUNITY What is the importance of knowing the normal flora in terms of dealing with infections? Answer: It helps in determining EMPIRIC THERAPY.
  • 38. 38 Antibiotic Classes 32 Case 1 • 35/male who was admitted for severe abdominal pain and fever. • Took paracetamol but did not improveER • PE: febrile, direct and rebound tenderness RLQ
  • 39. 39 32 Case 1 • A> Acute appendicitis  underwent OR • He was discharged improved. • On ff-up with the surgeon after 5 days, STAPHYLOCOCCUS
  • 40. 40 Staphylococcus aureus • frequently found in the human respiratory tract and on the skin • NOT always pathogenic • Causes skin infections (e.g. boils), respiratory disease (e.g. sinusitis), and food poisoning • Producing potent toxins • Common cause of device-related infections • Carriage in healthy individuals (nostrils) • The emergence of antibiotic-resistant forms of pathogenic S. aureus (e.g. MRSA) is a worldwide problem in clinical medicine. Staphylococcus aureus • Virulence factors – Coagulase – Staphylokinase – Hyaluronidase
  • 41. 41 Coagulase and Staphylokinase Staphylokinase Staphylokinase Clotting protein 36 Hyaluronidase (Spreading factor) Hyaluronidase digests hyaluronic acid, the “glue” that holds cells together 37
  • 42. 42 Clinical manifestation of S. aureus infection 38 40
  • 43. 43 Staphylococcus aureus 1. Local Stap. Infection – drainage > antibiotics –semi synthetic PCN Cloxacillin Erythromycin Cehalosporin (1st gen.) 2. Systemic Infection: Parenteral Vancomycin Oxacillin Methiallin Cephalosporin Question What is the current MRSA rate in the Philippines according to the ARSP 2014? A. <5% B. 35% C. 60% D. 90%
  • 44. 44 Question What is the current MRSA rate in the Philippines according to the ARSP 2014? A. <5% B. 35% C. 60% D. 90% Percent resistance of S. aureus, (n=3,529), ARSP, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM 2014 ANNUAL REPORT FIGURE 32. Yearly penicillin, oxacillin and vancomycin resistance rates of S. aureus, ARSP, 2005-2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT, Research Institute for Tropical Medicine, Department of Health Philippines
  • 45. 45 Percent resistance of S. aureus, (n=3,529), ARSP, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT, Research Institute for Tropical Medicine, Department of Health Philippines Percent resistance of S. aureus, ARSP, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM 2014 ANNUAL REPORT Antimicrobial Resistance The 2014 resistance rate of S. aureus against the β-lactam oxacillin is at 60.3% (n=3,323; 95% CI: 58.6-62). The 2014 rate of methicillin-resistant S. aureus (MRSA) rates increased significantly from 53.2% in 2013 to the 60.3% in 2014 (p value 0.0001). Resistance rates against the antibiotics tested against S. aureus for 2014 and the past decade are see n FIGURES 40-43. The 2014 resistance rates to the rest of the antibiotics tested did not differ significantly from the reports from 2013 except for the significant increase in co-trimoxazole resistance from 14% in 2013 to 22% for 2014 (p value 0.0001). Although there were 17 isolates reported as vancomycin resistant, none of these S. aureus isolates were sent for confirmatory testing at the reference laboratory. FIGURE 30. Percent resistance against penicillins, vancomycin, clindamycin and erythromycin of S. aureus, ARSP, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE PROGRAM (ARSP) 2014 ANNUAL REPORT, Research Institute for Tropical Medicine, Department of Health Philippines • Overall cumulative MRSA rate for 2014 was at 60.3% (from 53.2%, p=0.0001) • 85% were isolated from specimens taken from patients in the OPD, emergency room and admission within their 1st 2 hospital days • 60% MRSA rate from all blood isolates (n=570)
  • 46. 46 Enterococci • Gram-positive cocci in chain 44 Enterococci • Gram-positive cocci in chain • Commensals of the GI tract of humans & animals • Diseases : • Consist of 16 species :- E. faecalis, E. faecium - Urinary tract infection (UTI) - Bacteremia, endocarditis 44
  • 47. 47 Vancomycin-Resistant Enterococci (VRE) 46 • An emerging pathogen but none yet in PH • Acquired via plasmids • Cephalosporin use is a risk factor • Can be carried by healthy people 32 Case 2 • 65/male DM, HPN admitted for sudden left sided weaknessER • PE: no motor movement left UE and LE, shallow right NSLF, slurred speech
  • 48. 48 32 Case 2 • Treated as stroke and underwent rehab after 5 days doing well • On Day 6 cough and difficulty of breathing, high fever, auscultation revealed rales on right lung field • Eventually intubated due to respiratory distress Case 2 • Started empirically on PipTazo • ETA GS revealed many PMNs and many Gram _____________.
  • 49. 49 Pseudomonas aeruginosa •Aerobic gram-negative bacilli, non- spore forming •Produces cyanin pigment •Produces grape-like odor •Inhabitant of the GI tract •Saprophytic (natural habitat: soil and water) •An opportunistic pathogen Pseudomonas aeruginosa •
  • 50. 50 • MOST important hospital-acquired pathogen • Other pseudomonads: Burkholderia mallei, Burkholderia cepacia •High tendency to develop antibiotic resistance Pseudomonas aeruginosa 21 Resistance Pattern of P. aeruginosa, ARSP 2011
  • 51. 51 23 • Causes nosocomial infections- extensive burns, trauma to the skin or conjunctiva, urinary tract manipulations • cystic fibrosis. • Ear infections – swimmer’s ear • Bacteremia in debilitated patients, accounts for 10% of all Gram(-) associated with a 50% mortality rate Pseudomonas aeruginosa 21
  • 52. 52 Treatment • Aminoglycosides • Third and fourth generation cephalosporins (ceftazidime, cefepime) • Carbapenems (imipenem, meropenem) • Pip-tazo • Colistin Pseudomonas aeruginosa Clinical manifestation of P. aeruginosa infections
  • 53. 53 32 Case 3 • 15/male with cerebral palsy recurrently admitted for pneumonia • He already has a tracheostomy tube in place • Developed progressive cough and respiratory distressER 32 Case 3 • PE: drowsy, highly febrile, rales all over R>L • Hooked to MV and started on Pip-Tazo
  • 54. 54 Case 3 • After 3 days of antibiotics, he was still febrile • Developed hypotension and further respiratory distress Case 4 • EC = few PMN=moderate • Gram negative diplococci-few • Gram negative coccobacilli-many
  • 55. 55 Acinetobacter • Aerobic gram-negative coccobacilli, non-spore forming • > 25 species • A common cause of ventilator- associated pneumonia (VAP) • Opportunistic pathogen 28 • Local isolates are very highly resistant to antibiotics A. baumannii Clinical manifestation of A. baumannii infection1.Hospital-acquired pneumonia especially VAP 2.Community-acquired pneumonia :The source of infection may be throat carriage, which occurs in 10% of community residents with excessive alcohol consumption 3.Bloodstream infection & endocarditis 4.Skin/soft tissue infection 5.UTI 6.Meningitis 29
  • 56. 56 A. baumannii Persistence in the hospital environment : 3 days to 5 months 1. Resistance to major antimicrobial drugs 2. Resistance to desiccation 3. Resistance to disinfectant Three factors contributing to the persistence 31 A. baumannii 31
  • 57. 57 A. baumannii Treatment: • Meropenem • Colistin • Tigecycline • Ampicillin-Sulbactam 31 Acinetobacter • Aerobic gram-negative coccobacilli, non-spore forming • > 25 species • A common cause of ventilator- associated pneumonia (VAP) • Opportunistic pathogen 28 • Local isolates are very highly resistant to antibiotics
  • 58. 58 A. baumannii Clinical manifestation of A. baumannii infection1.Hospital-acquired pneumonia especially VAP 2.Community-acquired pneumonia :The source of infection may be throat carriage, which occurs in 10% of community residents with excessive alcohol consumption 3.Bloodstream infection & endocarditis 4.Skin/soft tissue infection 5.UTI 6.Meningitis 29 A. baumannii Persistence in the hospital environment : 3 days to 5 months 1. Resistance to major antimicrobial drugs 2. Resistance to desiccation 3. Resistance to disinfectant Three factors contributing to the persistence 31
  • 59. 59 A. baumannii 31 A. baumannii Treatment: • Meropenem • Colistin • Tigecycline • Ampicillin-Sulbactam 31
  • 60. 60 Enterobactereaceae • Gram-negative, nonspore-forming rods • Facultative anaerobic • Grow in simple media (MacConkey agar) • Ferment glucose (LF) • Motile with peritrichous flagella except Shigella • Some possess capsule Impt. Human pathogens • Escherichia - E. coli • Enterobacter (E. aerogenes, E. cloacae) • Citrobacter - C. freundii • Serratia - S. marcescens • Hafnia - H. alvei • Klebsiella
  • 61. 61 *Proteus Group – P. mirabilis – P. vulgaris – Morganella – M. morganii – Providencia – P. rettgeri *Edwardsiella – E. hoshinae Escherichia coli • Escherichia coli and certain related bacteria (e.g., Klebsiella, Enterobacter, Citrobacter) form the group known as the coliforms • presence in drinking water is considered evidence of fecal contamination • used as an index of fecal pollution.
  • 62. 62 Epidemiology • Fecal-oral transmission transmission among infants in hospital nurseries. • Food-borne transmission of E. coli 0157:H7 - contaminated meat, from cattle; this serotype behaves as a zoonotic agent. • UTI –perineum; In women, UTI is associated with sexual activity, hence the term "honeymoon cystitis". Diseases associated with Escherichia coli: • Diarrhea • Meningitis – impt. cause of neonatal meningitis in the neonates • Sepsis • Urinary Tract Infection -most common cause
  • 63. 63 Gram’s Stain and Culture Klebsiellae • Encapsulated • The species of Klebsiella include - Klebsiella pneumoniae- most infections -Klebsiella oxytoca -Klebsiella ozaenae -Klebsiella rhinoscleromatis
  • 64. 64 • Mucoid colony • มีแคปซูลหนา Klebsiella 18 Diseases: • Community acquired and nosocomial pneumonia w/ underlying medical problems such as alcoholism, COPD or diabetes mellitus • Lung abscess may also develop. • Urinary tract infection • Wound infection • Epidemic diarrhea - newborns • Septicemia
  • 66. 66 Enterobacteriaceae: Treatment • Empiric therapy with aminoglycoside and third cephalosporin Case 4 • 35/female who just delivered a baby boy via NSD 1 week ago rushed back to the ER for severe hypogastric pain • PE: highly febrile, direct tenderness at the hypogastric area, purulent vaginal discharge • Diagnosis? • Started on meropenem and clindamycin (MRSA)
  • 67. 67 Case 4 • She underwent EL on Day 3 • Doing well • Day 10 of meropenem and clinda, developed high fever • No cough. No dysuria but she was having LBM 5-7x/day • Diagnosis? Clostridium Difficile • Gm (+) bacillus, obligate anaerobe • Spore forming contact precautions • Causes pseudomembranous colitis and antibiotic-associated diarrhea
  • 68. 68 Laboratory Diagnosis • Culture of stool specimens • Cytotoxin Assay – Tissue culture assay – immunoassays • Colonoscopy or Signoidoscopy with Biopsy Endoscopic findings – pseudomembranes and hyperemic rectal mucosa Treatment • Antimicrobial therapy should be discontinued • Maintenance of fluid & electrolyte balance • Avoid drugs which intestinal motility
  • 69. 69 • Drug of choice – Metronidazole (30 mg/day in 4 divided doses) – drug of choice in the initial treatment of most patients with colitis – Oral Vancomycin (40 mg/kg/day in 4 divided doses) – indicated only for seriously ill patients or those who do not respond to vancomycin – Bacitracin – ssecond alternative therapeutic choice Case 5 • 70/female post stroke and chronically bed ridden was admitted for decreased sensorium • Because of urinary incontinence, has been on foley catheter and PEG for episodes of aspiration • PE: drowsy, T 37 C BP 70/50 HR 100 • Clear breath sounds, no nuchal rigidity
  • 70. 70 Case 5 • Labs done: WBC 20 Neut 90% • Chest xray: normal • Urinalysis: WBC 50 RBC 0-3 EC few yeast cells few • Started on Ceftriaxone 1g IV q24h • FC was changed • Urine GS CS requested Case 5 • Urine GS: PMN many yeast cells few G+cocci in clusters many
  • 71. 71 Candida spp. • normal flora of the skin, mucous membranes, and gastrointestinal tract • colonize the mucosal surfaces of all humans during or soon after birth • Candida albicans – the most common pathogen • Others: C albicans, C tropicalis, C parapsilosis, C glabrata, C guilliermondii, and C dubliniensis) • The widespread use of fluconazole has precipitated the emergence of more azole-resistant species, such as C krusei and C lusitaniae. Cutaneous & Mucosal Candidiasis • The risk factors: AIDS, pregnancy, diabetes, young or old age, birth control pills, and trauma (burns, maceration of the skin), corticosteroids or antibiotics, hyerglycemia, and cellular immunodeficiency • Cutaneous candidiasis- when the skin is weakened by trauma, burns, or maceration. Vulvovaginitis - irritation, pruritus, and vaginal discharge; often preceded by factors such as diabetes, pregnancy, or antibacterial drugs that alter the microbial flora, local acidity, or secretions.
  • 72. 72 Systemic Candidiasis (Candidemia) • Causes: – indwelling catheters, surgery, intravenous drug abuse, aspiration, or damage to the skin or gastrointestinal tract • most often associated with: – chronic administration of corticosteroids or other immunosuppressive agents; with hematologic diseases such as leukemia, lymphoma, and aplastic anemia; or with chronic granulomatous disease Candidiasis: Treatment • Systemic candidiasis: amphotericin B with/without oral flucytosine, fluconazole, or caspofungin
  • 73. 73 Outline • Basic Bacteriology – Structure and Characteristics – Bacterial Culture • Host defenses • Gram positive Pathogens • Gram negative Pathogens • Bonus(es) 감사합니다!!!! ㅋㅋㅋ